Neurol. praxi. 2020;21(2):162-164 | DOI: 10.36290/neu.2020.063

Dlouhodobá účinnost a bezpečnost kladribinu v léčbě roztroušené sklerózy

MUDr. Zuzana Zafarová

Jedna z přednášek věnovaných léčbě roztroušené sklerózy (RS) na 33. českém a slovenském neurologickém sjezdu, který proběhl na konci listopadu 2019 v Praze, byla zaměřena na dosavadní vědecké poznatky i praktické zkušenosti s perorálním kladribinem. Prof. Eva Kubala Havrdová doložila, že pulzní léčba perorálním kladribinem (podávaná v 1. a 2. terapeutickém roce) u pacientů s RS významně snižuje výskyt relapsů, zpomaluje progresi disability a potlačuje aktivitu choroby na magnetické rezonanci. Na základě dlouhodobých dat ukázala, že podíl pacientů s dosažením NEDA (stav bez klinické aktivity choroby) přetrvává i ve 3. a 4. roce, kdy již není kladribin podáván. Nové poznatky doplnila o vlastní zkušenosti s kladribinem a potvrdila, že dlouhodobé sledování jeho bezpečnosti nenaznačuje žádná nová rizika.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Dlouhodobá účinnost a bezpečnost kladribinu v léčbě roztroušené sklerózy. Neurol. praxi. 2020;21(2):162-164. doi: 10.36290/neu.2020.063.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018; 11: 1756285617753365. Go to original source... Go to PubMed...
    2. Cook S, Giovannoni G, Leist T, Comi G, Syed S, Nolting A, Damian D, Schick R. Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data. ECTRIMS Online Library. Sep 13, 2019; 278591; P1390. Go to original source...
    3. Giovannoni G, Comi G, Rammoha K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D. Long-term disease stability assessed by the expanded disability status scale in patients treated with Cladribine tablets in the CLARITY and CLARITY extension studies. ECTRIMS Online Library. 2019; 279715; EP1573. Go to original source...
    4. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S. CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011; 10(4): 329-337. Go to original source... Go to PubMed...
    5. Giovannoni G, Keller B, Jack D. Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY extension. ECTRIMS Online Library. 2018; 11: 228737; P894. Go to original source...
    6. Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler. 2019; 25(6): 819-827. Go to original source... Go to PubMed...
    7. Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018; 24(12): 1594-1604. Go to original source... Go to PubMed...
    8. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014; 13(3): 257-267. Go to original source... Go to PubMed...
    9. Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018; 5(5): e477. Go to original source... Go to PubMed...
    10. PREMIERE registry. https://clinicaltrials.gov/ct2/show/NCT0101335025. Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord. 2019; 29: 157-167.26. Go to original source... Go to PubMed...
    11. SPC kladribin. www.sukl.cz.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.